RecruitingNot Applicable

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

United States100 participantsStarted 2025-04-14

Plain-language summary

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men, Women, and all genders * Individuals 18 years old or older are included. * Patients of the study investigators and team members * Diagnosis of pancreatic ductal adenocarcinoma * All subjects must consent to this study * Clinically diagnosed weight loss Exclusion Criteria: * Minors * Pregnant Women * Any records flagged "break the glass" or "research opt out." * Patients who have received treatment for SIBO in the past 3 months

What they're measuring

SIBO in PDAC

Timeframe: At Screening Visit

Trial details

NCT IDNCT06988150

SponsorCedars-Sinai Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-04-14

Contact for this trial

Abrahm Levi

310-248-8084 abrahm.levi@cshs.org

View on ClinicalTrials.gov More Pancreatic Adenocarcinoma trials